ASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170608005378/en/
As part of this pilot program,
"We are excited to designate Foundation Medicine's CGP assays as providing reports that are optimized for TAPUR participation and work with
"The TAPUR Study's innovative, biomarker-driven design will expand access for patients to innovative new targeted therapies, while enhancing the collective understanding of the genomic basis of cancer biology," said
About the TAPUR™ Study
The TAPUR Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. The TAPUR Study provides approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies, catalogues the choice of genomic profiling test by clinical oncologists and aims to learn about the utility of registry data to develop hypotheses for additional clinical trials.
About ASCO:
Founded in 1964, the
About
Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. Foundation Medicine's SmartTrials program helps clinical research sponsors design, plan and implement clinical trials using Foundation Medicine's oncology knowledge base and physician network. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
ASCO®, American Society of Clinical Oncology® and TAPUR™ are trademarks of
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the value and performance capabilities of Foundation Medicine's comprehensive genomic profiling assays; the ability of CGP and the SmartTrials services to help accelerate clinical trial enrollment; and the ability of a clinical trial, including the clinical trial design, to expand access to therapies or improve cancer care. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that
View source version on businesswire.com: http://www.businesswire.com/news/home/20170608005378/en/
ASCO Media Contact:
Aaron.Tallent@asco.org
or
Foundation Medicine Media Contact:
pr@foundationmedicine.com
or
Foundation Medicine Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media